Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VH4V
|
|||
| Former ID |
DNCL002928
|
|||
| Drug Name |
Teplizumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10] | Approved | [1] | |
| Melanoma [ICD-11: 2C30] | Phase 3 | [2] | ||
| Company |
Provention Bio
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761183. | |||
| REF 2 | ClinicalTrials.gov (NCT00920582) Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.